Wednesday, 19 June 2019
#Cannabis and OTC Medications Sector Snapshot-More Health Canada Approval with Rise of Cannabis/Wellness Market (OTCQB: $INNV) (NASDAQ: $NEPT) (OTCQX: $WDDMF) (NASDAQ: $KOOL)
#Cannabis and OTC Medications Sector Snapshot-More Health Canada Approval with Rise of Cannabis/Wellness Market (OTCQB: $INNV) (NASDAQ: $NEPT) (OTCQX: $WDDMF) (NASDAQ: $KOOL)
Point Roberts WA, Delta BC – June 19, 2019 - Investorideas.com, a leading investor news resource covering biotechnology, pharmaceutical and cannabis stocks releases a sector snapshot reporting on how, as the now legalized cannabis industry has gained heavy traction federally with Health Canada approvals, this potentially helps open the doors for other OTC medications and wellness products.
Companies featured include Innovus Pharmaceuticals, Inc. (OTCQB: INNV), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), WeedMD Inc. (TSXV:WMD) (OTCQX:WDDMF) and Cesca Therapeutics (NASDAQ: KOOL).
Innovus Pharmaceuticals, Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, recently announced that it has made significant progress on the regulatory and manufacturing steps needed to obtain market authorization from Health Canada to commercialize its FlutiCare® brand in Canada. The Company expects to secure the needed market authorization, manufacturing and supply of the product from an existing Canadian manufacturer during the second half of 2019, pending Health Canada approval. The product is expected to be available as an over the counter drug (“OTC”) in that country and will not require a prescription.
Read this in full at https://www.investorideas.com/news/2019/cannabis/06192OTCMedications-WellnessMarket.asp
“We are pleased to announce progress relating to our plans to commercialize FlutiCare® in Canada as this is will be our first international market for the product if approved by Health Canada,” said Innovus Pharma CEO, Dr. Bassam Damaj. “In addition to Canada, we are working with the regulatory bodies of several other countries to assess the requirements needed to file for market authorization in those countries.”
In addition to FlutiCare®, the Company recently jointly announced with its former distribution partner, Acerus Pharmaceuticals, Inc., (a Canadian company [“Acerus”]), that it would be receiving back all the rights to its product UriVarx®, approved for the relief of symptoms of overactive bladder and urine incontinency by Health Canada. “Receiving the rights to the product back from Acerus, which allows Innovus Pharma to fully commercialize it under our sales and marketing platform, was the most logical step for us to take to ensure the full market potential of UriVarx® in Canada. We currently expect additional revenues of at least $1.5 million a year from the sales of the product in Canada versus the $0.5 million recognized for the previous year,” added Dr. Damaj.
“The Company continues to assess the performance of its partners in Canada and around the world and will continue to take steps to ensure that they perform to achieve maximum sales potential of our products. To that effect, the Company will no longer supply Apeaz® to Showcase, Inc., (a Canadian company), as the marketing requirements through their platform as compared to the sales achieved by them from this product were not satisfactory to Innovus Pharma. Under our sales and marketing platform, Apeaz® is now our second-best performing product in Canada that we sell directly there, after Diabasens® and is on track to achieve over $2 million in revenues for 2019,” stated Dr. Damaj.
The Company has 13 products approved and commercialized in Canada including Zestra®, Zestra Glide®, Uxor®, DiabaSens®, Vesele®, RecalMax®, UriVarx®, ProstaGorx®, BH Testosterone®, AllerVarx®, Xyralid® Cream, Xyralid® Suppositories, and Apeaz® and has filed or is in the process of filing for six additional products including, FlutiCare®, PeVarx®, Healthifeet®, Breastlift®, ArthriVarx® and CarvaNum™.
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) recently announced that its wholly owned subsidiary, 9354-7537 Quebec Inc. has received a notification letter from Health Canada indicating that all requested license amendments have been approved.
The scope of the amendment received from Health Canada permits expansion of cannabis operation areas to include an additional extraction room where Neptune will perform cold ethanol extraction. Ethanol extraction is faster and more cost effective than the CO2 extraction currently used and will increase Neptune's input capacity from 30,000 kg to 200,000 kg.
The amendment from Health Canada also includes expansion for an encapsulation room where Neptune will produce cannabis oil capsules using the Licaps® technology licensed from Lonza Group AG. The encapsulation equipment is commissioned and ready for commercial operations with a capacity of up to 200 million capsules annually. The Licaps® technology supports differentiated product offerings through its various delivery systems, colors and branding possibilities. Furthermore, this is an effective technology for variable and multiple product formulation runs.
Neptune's Board of Directors recently approved an investment of $7 million to establish additional formulation, manufacturing and packaging infrastructure. This investment will allow Neptune to provide formulation services for new expected product forms such as vape pens, topicals, beverages, sprays, and others. A $4 million investment has also been approved, due to strong customer demand, to increase extraction capacity to a total of 1,500,000 kg, under Neptune's Phase IIIA expansion plans, targeted for completion before the end of calendar year 2019.
With this approval, Neptune is now positioned to submit further license amendments to incorporate the manufacturing of additional product forms, and packaging capabilities, as well as for the Phase IIIA extraction capacity expansion.
Another Cannabis company, WeedMD Inc. (TSXV:WMD) (OTCQX:WDDMF), a federally-licensed producer and distributor of medical-grade cannabis who recently secured Health Canada approval for 27 acres of low-cost, outdoor cultivation on its Strathroy, Ontario property, recently announced that it is the first licensed producer (LP) to be included in Shoppers Drug Mart and TruTrace Technologies’ medical cannabis verification pilot project.
As recently announced by Shoppers and TruTrace at The Second Annual World Cannabis Congress, the Pilot Project is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products. Link here to read. WeedMD has been a medical cannabis supplier to Shoppers since February 2019 and was the first licensed producer to partner with TruTrace and utilize the StrainSecure™ platform to register its genetics in late 2018.
“We registered 40 of our proprietary cannabis strains with TruTrace last October, recognizing the importance of strain validation as cannabis products advance through the medical and pharmaceutical channels,” said Keith Merker, CEO of WeedMD. “We’re proud to be the first LP to be included in Shoppers and TruTrace’s recently announced pilot project. Patients and their medical practitioners expect traceability and origin assurance of their cannabis strains as it goes a long way to building continued trust and accountability in our industry.”
ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (NASDAQ: KOOL) and a market leader in automated cellular processing recently announced that it has received Health Canada approval of its next-generation AXP®II system for cord blood processing.
The AXP® II, together with the company's companion, single-use, cell separation set, provides automated, rapid and reproducible harvesting of stem and progenitor cells from collected units of umbilical cord blood in a "functionally-closed" sterile system. The system, which received 510(k) market clearance from the US Food & Drug Administration (FDA) in November 2018, is used by premier public and private cord blood banks worldwide. It provides customers with upgraded functionality, user interface and compatibility with newer operating systems, and features an improved docking station and XpressTRAK® software to maintain compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.
Haihong Zhu, President of ThermoGenesis stated, "Health Canada's approval of the AXP® II - following its approval of the PXP® System earlier this year - marks the achievement of yet another key milestone and should allow us to meaningfully expand our footprint with a best-in-class system that today continues to hold a market-leading position. That said, we look forward to building on our customer base by offering Cord Blood Banks throughout Canada with the ability to undertake cord blood processing with a system that generates mononuclear cell (MNC) recoveries of >90% and CD34+ stem and progenitor cell recoveries of > 95%."
With the current Canadian federal legalization of cannabis and the forthcoming expected regulation updates due this October, both the pharmaceutical and wellness sectors are taking notice and following some of the same paths towards approval in the legal cannabis market. While this may be beneficial to those companies in the cannabis, pharmaceutical and wellness sectors, the real winner will be the Canadian consumer, who will no longer be cornered into having only one option as their medical/health treatment.
Investorideas.com has created a directory of publicly traded cannabis and biotech companies to research as part of its membership. Learn more at https://www.investorideas.com/membership/
About Investorideas.com - News that Inspires Big Investing Ideas
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this article featuring INNV is a paid for service on Investorideas.com ( two thousand ) by a third party. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact Investorideas.com
800-665-0411
Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories
Tuesday, 18 June 2019
Investorideas.com - High-yielding CBD hemp farming project on 35-acre land in Scio, Oregon - Marijuana Company of America Inc. (OTC: $MCOA), Global Hemp Group (CSE: GHG/ OTC: $GBHPF)
Investorideas.com - High-yielding CBD hemp farming project on 35-acre land in Scio, Oregon - Marijuana Company of America Inc. (OTC: $MCOA), Global Hemp Group (CSE: GHG/ OTC: $GBHPF)
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - Breaking Cannabis News: New Frontier Data and PwC Canada Join Forces to Bring Data-Analytics and Business Intelligence to the Cannabis Industry
Investorideas.com - Breaking Cannabis News: New Frontier Data and PwC Canada Join Forces to Bring Data-Analytics and Business Intelligence to the Cannabis Industry
www.investorideas.com - News that inspires big Ideas
www.investorideas.com - News that inspires big Ideas
Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (TSXV: $OGI.V) (NASDAQ: $OGI) (TSXV: $META.V)( CSE: $CRFT.C) (CSE: $TIM_U.C)
Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move
(TSXV: $OGI.V) (NASDAQ: $OGI) (TSXV: $META.V)( CSE: $CRFT.C) (CSE: $TIM_U.C)
Delta, Kelowna, BC –June
18, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/06181OGI-META-CRFT-TIM.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
Today we are looking at a few early
announcements.
But first, The Global Cannabis Partnership
(GCP), a collaboration of leaders in the government-sanctioned cannabis
industry,
released today a
corporate social responsibility framework that its 45-member organizations have
agreed to adhere to, establishing a standard for the new and rapidly growing
cannabis industry worldwide.
"We're building an industry for the
future," said the GCP's Executive Director Kim Wilson. "It's one
thing to have a legal license to operate; earning and keeping a social license
is another story. We have a long road ahead of us, but today's announcement is
an important step in the right direction."
The world's first Responsible Cannabis
Framework (RCF) seeks to positively influence the industry's impacts on the
environment and society, and aims to support GCP members in continually
improving their corporate performance over time.
Using best practices from within and
outside the industry, the RCF goes beyond minimum compliance with all relevant
and applicable laws, articulating expectations of members for evaluating,
developing, implementing, measuring and disclosing their environmental, social
and governance initiatives.
"The RCF was developed through
extensive research and consultation with a variety of stakeholders," said
Rick Petersen, one of the world's experts in corporate responsibility and
author of the Framework. "We knew that we could rely on the experience of
other industries, while at the same time coming up with the right steps to meet
the challenges in our specific sector."
Members have all agreed to the Framework's
four guiding principles – responsibility, collaboration, transparency and
continuous improvement – and have up to a year to complete work necessary to
apply for one of four certification categories. Minimum requirements include,
among others, minimizing greenhouse gas emissions; promoting responsible use,
and reinforcing ethical conduct. The formal certification process was developed
by EY and member applications will be submitted to an independent evaluation
panel.
The GCP expects members to make
improvements when Framework standards are not met and to develop mechanisms to
ensure ongoing compliance and continuous improvement.
Organigram Holdings
Inc. (TSXV: OGI) (NASDAQ: OGI), the
parent company of Organigram Inc., a leading licensed producer of cannabis, announced that
it has signed an exclusive agreement with Feather Company Ltd., a cannabis
innovator and lifestyle brand committed to the production of premium-quality
products that enhance the cannabis experience for customers. The disposable
vaporizer pen and 5/10 thread cartridges for targeted adult-use customer
segments will be available following legalization of this product category
currently scheduled to come into effect as of October
2019.
Organigram,
through the Edison Cannabis Co. brand, has an exclusive license to Feather's
proprietary vaporizer pen technology and form factor. The relationship will
also allow Organigram to represent Feather across Canada from a commercial
perspective. This agreement reflects both companies' commitment to
transformative thinking and unique customer experiences.
"A
successful recreational cannabis market requires that licensed producers and
their partners continually reimagine the cannabis experience," says Ray
Gracewood, Senior Vice President, Marketing and Communications, Organigram.
"It is critical for Organigram to find unique ways to offer customers the
kind of value that will help differentiate our brands. The future is in
providing unique opportunities for customers to explore the product."
Feather's technology and hardware offers
Organigram's Edison brand a unique, proprietary delivery mechanism for
discerning and sophisticated consumers and will compliment the companies
recently announced partnership with PAX, a leader in closed-loop vaporizable
technology offered through the PAX Era product line.
National Access Cannabis Corp. (TSXV: META),
Canada's largest cannabis retailer according to provincial licensing
statistics, today announced it
has received three additional licences from the Alberta Gaming, Liquor and
Cannabis Commission to open cannabis retail stores in Alberta. The retail
stores will be located in the cities of Calgary, Edmonton and Airdrie. The
announcement comes following the previously released news that the AGLC has
lifted the moratorium on new cannabis retail licences.
"We're growing rapidly in
Alberta," said Mark Goliger, CEO of NAC. "With three new licences and
the new location recently opened June 5th in the Varsity
neighbourhood in Calgary, we continue to expand our private cannabis retailing
footprint in Alberta and our growth isn't done. We have 15 additional licences
submitted and 7 more stores built awaiting licensing and regulatory approval in
Alberta."
NAC is the national leader in retail
cannabis. Currently operating in three provinces, NAC has applied for licences
in British Columbia and plans to make applications for licences in Ontario once
licensing opens up to more private retailers. NAC's experienced team of retail
industry professionals is focused on achieving its business plan of having 40
operating stores by the end of calendar 2019, and 110 operating stores by the
end of calendar 2020.
Pasha Brands Ltd. (CSE: CRFT) (OTC:CRFTF) introduced BC
Craft Supply Co. Ltd. as the first in its line of nearly a dozen leading craft
cannabis brands that aim to rectify Canada's ongoing product shortage and
quality issues. Through its subsidiaries, Pasha is Canada's first licensed
producer exclusively focused on assisting the original cannabis industry in
Canada in gaining access to the regulated market through Health Canada's new
micro cultivation licensing regime.
BC Craft is helping Canada's leading
cannabis growers acquire micro-cultivation licences by providing comprehensive
support and advice, as well as all necessary testing, processing and packaging
to help growers legally bring their products to market. With Pasha's recent
acquisition of Medcann Health Products Ltd., a fully licensed, Health Canada
approved facility, BC Craft is uniquely positioned to work with the thousands
of craft producers in Canada that are now looking to transition into Canada's
new regulated supply chain.
"I'm confident that what BC Craft
Supply Co. will be able to contribute to the legal market will set the standard
for craft production and supply chain management, not just in Canada but
internationally," said Jason Longden, CEO of Pasha Brands.
"Confidence in the brand has already inspired craft cultivators throughout
British Columbia and from across the country to join our team, and we're eager
to help solve Canada's ongoing supply issue with quality cannabis the legal
market has yet to see."
Representing the first wave of Pasha's
industry-shaking craft cannabis brands, BC Craft is a service provider in
contract with some of Canada's best farmers to ensure their timely
participation and competitive edge in Canada's burgeoning legal cannabis market.
Spurred by a passion to support small businesses and pay respect to the
cultivators that have always been the country's top choice for quality
cannabis, the brand is working to assist in their transition into the market so
that consumers can have legal access to legitimate and sought-after 'BC Bud' at
long last.
With Medcann now part of the Pasha group,
BC Craft will coordinate the purchase of craft cannabis from licensed micro
cultivators under a supply agreement, kicking off the transition from the unregulated
market—where nearly 85 percent of all cannabis sales in Canada still take
place—to the legal one. Once micro cultivators are licensed and operational, BC
Craft anticipates an annual supply of approximately 50,000 kilograms of
cannabis per 100 micro cultivators in its supply chain. Industry estimates
place the number of grey market producers in BC alone at as many as 20,000.
Jose
Hidalgo, Founder and CEO of Cansortium
Inc. (CSE: TIUM-U), a
vertically-integrated, global provider of premium-quality medical cannabis
operating under the Fluent™ brand, issued the following statement in
response to Texas Governor Greg Abbott's signing of HB 3703 which expands
access to low-level THC (less than 0.5%) cannabis products to benefit Texas
residents coping with certain chronic medical conditions.
"The
Cansortium team is excited to work with the State of Texas to provide
cultivation, processing and home delivery operations in Texas in order to bring
the benefits of our premium-grade, low-level THC, cannabis products to Texas
residents who are coping with chronic medical conditions. As one of the three
medical cannabis licensees in the state of Texas, our company is also
well-positioned to begin building a network of conveniently located
dispensaries in key markets where authorized under the new law by the Texas
Department of Public Safety."
The
new law, which is now effective, contains the following three key provisions
that, together, are expected to increase legal access to low-level THC medical
cannabis products:
1.
Expands the range of medical conditions for which licensed specialty physicians
may recommend low-level THC cannabis products (containing up to 0.5 percent
THC). In addition to intractable epilepsy, which was previously the sole
eligible condition, the following additional chronic conditions now qualify for
cannabis recommendation:
●
All
forms of epilepsy
●
Terminal
Cancer
●
Amyotrophic
Lateral Sclerosis (ALS)
●
Incurable
neurological disease
●
Parkinson's
Disease
●
Multiple
Sclerosis
●
Autism
● Seizure disorders
2.
Enables a patient to gain access to medical cannabis products based on the
recommendation of a single licensed specialty physician, versus the previous
requirement that a patient obtain recommendations from at least two licensed
physicians.
3. Authorizes the Texas Department of Public
Safety to oversee approval, regulation and administration of cannabis
dispensaries to be constructed and operated by the state's three medical
cannabis licensees, which include Cansortium.
Cansortium
currently provides home-delivery services across Texas from a 4,000 square-foot
cultivation facility and adjacent 650 square-foot processing facility in
Schulenburg, Texas, with the ability to expand the cultivation facility up to
an additional 200,000 square-feet to meet incremental demand.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T...